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Abstract
Background: Tumor employs various means to escape immunosurveillance and inhibit immune attack, and
strategies have been developed to counteract the inhibitory signals. However, due to the complex suppressive
mechanisms in the tumor microenvironment, blocking one or a few inhibitory signals has only limited effects on
therapeutic efficacy. Instead of targeting tumor immunosuppression, we considered from another point of view,
and hypothesized that manipulating T cells to make them resist any known or unknown suppressive mechanism
may be more effective for cancer treatment.
Methods: We used OT-1 cells transduced with retroviruses encoding Akt and human peripheral blood lymphocytes
(PBLs) transduced with retroviruses encoding both Akt and a chimeric antigen receptor (CAR) specific for tumor
antigen EpCAM to examine the effect of over-expressing Akt on tumor specific T cells in tumor environment.
Results: We show that Akt activity of T cells in the tumor environment was inhibited, and over-expressing Akt in
OT-1 cells increased the cytokine production and cell proliferation in the presence of B16-OVA tumor cells. What’s
more, adoptive transfer of OT-1 cells over-expressing Akt inhibited B16-OVA tumor growth and prolonged mouse
survival. To examine if over-expressing Akt could increase the anti-tumor activity of T cells in human cancer, PBLs
co-expressing EpCAM specific CAR and Akt were cultured with EpCAM-expressing human prostate cancer cells
PC3M, and less inhibition on cell proliferation and less apoptosis were observed. In addition, adoptive transfer of
PC3M specific T cells over-expressing Akt resulted in more dramatic tumor inhibitory effects in PC3M bearing
NOD/SCID mice.
Conclusions: These data indicates that over-expressing Akt in tumor specific T cells increases T cell proliferation
and activity in the tumor environment, and enhances anti-tumor effects of adoptively transferred T cells. Our study
provides a new strategy to improve the efficacy of adoptive T cell therapy, and serves as an important foundation
for clinical translation.
Background
Tumor immunosuppressive microenvironment is the
major obstacle for successful clinical translation of immu-
notherapeutic approaches. Tumor employs different strat-
egies to escape immunosurveillance, including impairment
of the antigen presentation, up-regulating negative co-
stimulatory signals, secretion of immunosuppressive fac-
tors, activation of pro-apoptotic pathways, and recruitment
of different regulatory cell populations [1, 2]. By these
various means, tumor induces a complex immunosuppres-
sive microenvironment to evade immune response and re-
strict the effectiveness of cancer vaccine and adoptive
transfer of tumor specific T cells.
With deeper understanding of the interactions between
tumor and immune system, therapeutic strategies have
been developed to resist immunosuppression, such as
using antibodies to block CTLA-4 or PD-1 signaling, inhi-
biting IDO activity, depleting regulatory T cells, etc. [3].
However, it’s easy to understand that, confronting such a
complex immunosuppressive microenvironment, strat-
egies targeting one or two inhibitory signals have only lim-
ited effects on therapeutic efficacy. Instead of dealing with
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multiple inhibitory factors, we considered if there is any
means to manipulate effector T cells to make them resist
any known or unknown immunosuppressive mechanism.
Through analysis of T cell signaling pathways, we found
that Akt is in the central node of immune modulation.
The serine/threonine kinase Akt (PKB) is utilized in a
variety of signaling pathways from T cell growth factors
such as IL-7R, and CD28 co-stimulatory signal [4, 5].
CD28 activation enables recruitment and activation of
phosphatidylinositol 3-kinase (PI3K), resulting in the
generation of phosphatidylinositol-3,4,5-trisphosphate
(PIP3), which recruits pleckstrin homology (PH) domain
containing proteins including Akt to the plasma mem-
brane. After recruitment to the plasma membrane, Akt
becomes phosphorylated and activated by PDK1, and
then plays an important role in diverse cellular processes
including cell survival, glucose metabolism, and cytokine
synthesis [6–8]. Besides co-stimulatory receptors, co-
inhibitory receptors also regulate Akt activation. Ligation
of CTLA-4 and PD-1 both inhibit Akt activity, suggest-
ing PI3K-Akt signaling is a major mechanism of immune
regulation [9, 10]. Consistent with this, it has been re-
ported that T cells expressing constitutively active Akt
displayed increased viability in the absence of stimula-
tion, and could grow rapidly and secrete cytokines in the
absence of CD28 co-stimulation [11].
Based on these findings, we hypothesize that up-
regulating Akt activity in tumor specific T cells could
help T cells resist tumor immunosuppression and im-
prove the anti-tumor effects of adoptive immunotherapy.
To test this hypothesis, we used two different tumor
models, B16-OVA tumor model and human prostate
cancer PC3M tumor model, and demonstrated that
over-expressing Akt in tumor specific T cells could in-
crease T cell proliferation and cytokine secretion when
co-cultured with tumor cells, and inhibit tumor growth
in vivo. Our data suggests over-expressing Akt in ef-
fector T cells as a new strategy to improve the efficacy of
adoptive T cell transfer for cancer.
Methods
Mice
OT-1 transgenic mice were purchased from the Jackson
Laboratory, C57BL/6 mice and NOD/SCID mice were
purchased from Vital River Laboratories. All mice were
maintained under specific pathogen-free conditions in the
animal facility of Cancer Institute, Chinese Academy of
Medical Sciences (CAMS), and all procedures for animal
experiments were approved by the Institutional Animal
Use and Care Committee of CAMS.
Cell lines
The OVA-expressing tumor cell line, B16-OVA, was
kindly provided by T.-C. Wu lab (Johns Hopkins
Medical Institutions, Baltimore, MD) [12], and cultured
in RPMI1640 supplemented with 10 % FBS, 2 mM L-
glutamine, 1 mM sodium pyruvate, 2 mM non-essential
amino acids, 50 units/ml penicillin and streptomycin.
PC3M cell line was purchased from ATCC, and main-
tained in culture with DMEM medium (Gibco) supple-
mented with 10 % FBS.
Retroviral vector construction and retrovirus preparation
PLNCX-myr-HA-Akt1 (William Sellers, Addgene plasmid
9005) and pLNCX-HA-Akt1 (William Sellers, Addgene
plasmid 9004) were obtained from Addgene [13]. PLNCX
empty vector was used as the control retrovirus. To con-
struct EpCAM specific CAR and Akt co-expressing con-
struct, HindIII/HpaI/BglII-IRES-XhoI/SalI/ClaI sequence
was synthesized (IRES sequence corresponds to 1119–
1693 of pIRES-G, with 1346G→C) and inserted into
HindIII/ClaI multiple cloning sites of pLNCX retroviral
vector to make pLNCX-IRES. EpCAM specific CAR con-
sisting of an anti-EpCAM scFv (sequence corresponds to
Genebank identifier AJ564232.1) [14], part of the extracel-
lular domain and the entire transmembrane and intracel-
lular domains of CD28, and the cytoplasmic domain of
CD3ζ (the CD28 and CD3ζ sequence included corre-
sponds to Genebank identifier HM852952.1) [15] was
synthesized and inserted into HindIII/BglII of pLNCX-
IRES to make pLNCX-CAR. Akt and myr-Akt were
cloned from pLNCX-HA-Akt1 and pLNCX-myr-HA-
Akt1 respectively, and inserted into XhoI/ClaI of
pLNCX-CAR to make pLNCX-CAR-Akt and pLNCX-
CAR-myr-Akt co-expressing constructs. Retroviruses
were prepared using Retrovirus Packaging Kit Ampho
(TaKaRa) and 293 T packaging cell line, following the
manufacturer’s instruction.
Retroviral transduction of OT-1 cells and human PBLs
Splenocytes and lymph node cells of OT-1 transgenic
mice were harvested, and red blood cells were removed
by RBC lysis buffer (Biolegend). CD8+ T cells were iso-
lated using mouse CD8a+ T cell isolation kit (Miltenyi
Biotec), and then were stimulated with 1 ug/ml anti-
mouse CD3 and 1 ug/ml anti-mouse CD28 antibodies
(Biolegend) for 2 days at 1 × 106 cells/ml in RPMI
medium (Gibco) supplemented with 10 % FBS, 1x non-
essential amino acid, L-glutamine, sodium pyruvate, and
penicillin-streptomycin, and 0.1 % β-mercaptoethanol.
For retrovirus transduction, 24-well plates were coated
with RetroNectin (TaKaRa) at 4 °C overnight according
to the product’s manual, and blocked with 2 % BSA at
room temperature for 30 min. After that, the plates were
added with retrovirus supernatants at 300 ul/well and
incubated at 37 °C for 6 h. Then the stimulated cells
were transferred to the pre-coated wells at 1 × 106 cells/ml
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and cultured at 37 °C for 5 days in the presence of
100 U/ml recombinant human IL-2.
For PBL preparation, donor blood was obtained from
healthy volunteers with consent from institutional re-
view board of Cancer Institute, Chinese Academy of
Medical Sciences, and written informed consent for par-
ticipation in the study was obtained from participants.
PBMCs were prepared by centrifugation of the blood on
Ficoll-Hypaque density gradients (Sigma-Aldrich), and
adherent cells were removed by plating in cell culture
plates for 2 h. Then the cells were stimulated with 1 ug/ml
OKT3 and 1 ug/ml anti-human CD28 antibodies
(Biolegend) at 1 × 106 cells/ml for 2 days, and transduced
with retroviruses as described above.
Western blot
Cell lysis was performed on ice for 30 min in RIPA buf-
fer with 1x protease inhibitor cocktail, 0.5 mM PMSF,
30 mM NaF, 1 mM Na3VO4 added freshly. After centri-
fugation at 1000 rpm at 4 °C for 10 min, the protein
concentration of the supernatant was determined by
BCA assay, and 40 ug of protein extract was subjected
to SDS-PAGE and western blot following standard pro-
cedures. Phospho-Akt (Ser473) Rabbit mAb (Cell Signal-
ing Technology), Akt (pan) Rabbit mAb (Cell Signaling
Technology), and β-actin antibody (Santa Cruz Biotech-
nology) were used at 1:2000 to probe the western blots.
RT-PCR and quantitative real-time PCR
Total RNA was extracted using the RNeasy Mini kit
(Qiagen) and was reverse transcribed using ReverTra
Ace qPCR RT Master Mix with gDNA Remover
(TOYOBO). PCR was performed with EmeraldAmp MAX
PCR Master Mix (TAKARA), and the following primers
were used: CAR, 5′- CCTTATGGTTACGACGAGTAT
GGTCTGG and 3′- AACAGTTTAGGAGGCTGCCCTG
GTTTCT; β-actin, 5′-AAGAGAGGCATCCTCACCCT
and 3′- TACATGGCTGGGGTGTTGAA. Real-time PCR
was performed with iTaq Universal SYBR Green Supermix
(BIO-RAD) using CFX96 Touch Real-Time PCR Detec-
tion System (BIO-RAD), and the primers were purchased
from GeneCopoeia (Catalog# HQPCS0002).
Flow cytometry
Cells were stained with FITC or PE-conjugated CD8,
IFN-γ, HLA-DR, CD80, B7-H1, TGF-β, IL-10 antibodies
following standard protocol. All antibodies were pur-
chased from Biolegend. CFSE cell proliferation kit (Life
Technologies) was used to determine cell proliferation,
and APC Annexin V apoptosis detection kit with PI
(Biolegend) was used to detect cell apoptosis. Cells were
analyzed by a FACS Calibur flow cytometer and Flowjo
software.
Luminescence imaging
Luciferase expressing cell line PC3M-luc was established
by transducing PC3M with retroviruses encoding lucifer-
ase and selection with G418. To examine the cytotox-
icity of PBLs transduced with different retroviruses,
PC3M-luc cells were incubated with effector cells for
24 h, and then luciferin (Promega) was added at a final
concentration of 0.3 mg/ml. 10 min later, luminescence
imaging was conducted on IVIS system (Xenogen/Caliper
Life Sciences).
Statistical analysis
Data are presented as mean ± SE. To determine the sig-
nificance of differences between samples or groups, the
student’s t-test or two-way ANOVA was used as indi-
cated in the figure legends.
Results
Akt expression in the T cells is down-regulated in the
tumor microenvironment
To verify that Akt activation in T cells is inhibited in
tumor environment, T cells were isolated from OT-1
transgenic mice, stimulated with anti-CD3 and anti-
CD28 antibodies, and then incubated with B16-OVA
tumor culture medium supernatant. 24 h later, the levels
of phosphorylated Akt were determined by western blot.
As shown in Fig. 1a, incubation with B16-OVA culture
supernatant inhibited Akt phosphorylation, suggesting
that Akt activation in T cells is inhibited by tumor se-
creted factors. To examine Akt activation state of T cells
in tumor microenvironment in vivo, T cells were isolated
from tumor draining lymph nodes (TDLN) and distant
lymph nodes (LN) of B16-OVA tumor bearing mice, and
Akt phosphorylation was detected. As we expected, the
phosphorylation of Akt was down-regulated in TDLN
comparing to distant LN (Fig. 1b).
Over-expressing Akt in OT-1 cells enhances anti-tumor
effect in mouse B16 melanoma model
To examine if up-regulating Akt activation could in-
crease the activity of T cells in the presence of tumor, we
transduced OT-1 cells with retroviruses encoding wild
type Akt (wtAkt) or a constitutively active form of Akt
(myristoylated Akt, myr-Akt), and incubated the trans-
duced OT-1 cells with B16-OVA tumor cells. As shown
in Fig. 2a, when co-cultured with B16-OVA, OT-1 cells
transduced with either wtAkt or myr-Akt produced
more IFN-γ than OT-1 cells transduced with control ret-
roviruses. In the proliferation assay, OT-1 cells trans-
duced with control retroviruses slowed proliferation on
exposure to B16-OVA tumor cells, whereas OT-1 cells
transduced with either wtAkt or myr-Akt displayed higher
proliferation rates when cultured alone, and further in-
creased the percentage of proliferative populations when
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co-cultured with B16-OVA (Fig. 2b). Together, these data
demonstrates that over-expressing Akt or myr-Akt could
increase the cytokine production and proliferation of
tumor specific T cells in the presence of tumor.
To investigate if transducing wtAkt or myr-Akt could
improve the therapeutic effect of adoptively transferred
T cells against tumor, C57BL/6 mice were inoculated
with B16-OVA tumor cells subcutaneously, when tumor
size reached ~6 mm, in vitro stimulated and expanded
OT-1 cells transduced with control retroviruses or retro-
viruses encoding wtAkt or myr-Akt were intratumorally
injected into mice. As shown in Fig. 3a, adoptive transfer
of control OT-1 cells didn’t inhibit tumor growth com-
paring to the untreated group, whereas transducing
wtAkt significantly increased the anti-tumor effect and
prolonged mouse survival (Fig. 3b).
Human T cells engineered to over-express Akt exert
enhanced anti-tumor activity
To verify the above findings and further characterize the
mechanisms by which wtAkt or myr-Akt transduced T
cells resist tumor immunosuppression, we used the
human prostate cancer model we established previously
in our lab [16]. Prostate cancer cell line PC3M highly ex-
presses EpCAM, and human peripheral blood lympho-
cytes (PBLs) were engineered to recognize PC3M by
transducing with EpCAM specific chimeric antigen re-
ceptor (CAR) which consists of an anti-EpCAM scFv,
part of the extracellular domain and the entire trans-
membrane and intracellular domains of CD28, and the
cytoplasmic domain of CD3ζ. As shown in Fig. 4a,
PC3M lacks expressions of HLA-DR and CD80, whereas
expresses high levels of B7-H1, TGF-β, and IL-10. To
enhance the anti-tumor activity of PBLs expressing
EpCAM specific CAR against the immunosuppressive
PC3M tumor, we generated CAR-Akt, or CAR-myr-Akt
co-expressing retroviral vectors (Fig. 4b), and verified
the transduction efficiency of CAR and Akt in PBLs by
RT-PCR, real-time PCR and western blot, respectively
(Fig. 4c). The transduction efficiency of CAR was also
examined by staining with protein L, which is an im-
munoglobulin binding protein that can be used to deter-
mine CAR expression [17] (Additional file 1: Figure S1).
Since it was reported that Akt inhibition promotes T cell
differentiation to a memory phenotype [18], we evalu-
ated CD62L expression in transduced T cells. As shown
in Additional file 2: Figure S2, Akt over-expression
didn’t down-regulate the level of CD62L.
To determine if co-expressing Akt or myr-Akt could
help PBLs resist tumor immunosuppression, PBLs trans-
duced with CAR, CAR-Akt, or CAR-myr-Akt were co-
cultured with PC3M tumor cells, 3 days later, T cell
proliferation and apoptosis were examined. As shown in
Fig. 5 and Additional file 3: Figure S3, T cell prolifera-
tions were all inhibited in the presence of tumor cells,
however, the degree of inhibition was less in T cells co-
expressing Akt or myr-Akt. In addition, incubation with
tumor cells increased cell apoptosis in all groups, how-
ever, T cells co-expressing Akt displayed less apoptosis
comparing to T cells expressing CAR only, and T cells
transduced with myr-Akt displayed higher apoptosis rate
than T cells transduced with wtAkt, suggesting that trans-
ducing wtAkt may be more beneficial than myr-Akt.
Next, we examined the anti-tumor effects of PBLs co-
expressing Akt or myr-Akt both in vitro and in vivo.
PBLs transduced with CAR, CAR-Akt, or CAR-myr-Akt
Fig. 1 Akt activity of T cells is down-regulated in tumor environment. a CD8+ T cells isolated from OT-1 transgenic mice were stimulated with
anti-CD3 and anti-CD28 antibodies for 2 days, and then incubated with or without B16-OVA tumor cell culture supernatant. 24 h later, cells were
collected, and the levels of Akt, phosphorylated Akt, and β-actin were examined by western blot. b CD8+ T cells were isolated from tumor draining
lymph nodes (TDLN) or distant lymph nodes of B16-OVA tumor bearing mice, the levels of Akt, phosphorylated Akt, and β-actin were examined by
western blot
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were incubated with luciferase-expressing stable cell line
PC3M-luc, 24 h later, cytotoxicity was determine by
luminescence imaging. As shown in Fig. 6a, PBLs co-
expressing Akt caused more cell lysis than PBLs express-
ing CAR only. In NOD/SCID mice, PC3M tumor cells
were inoculated subcutaneously, when tumor size
reached ~3 mm, PBLs transduced with CAR, CAR-Akt,
or CAR-myr-Akt were injected intratumorally. As shown
in Fig. 6b, PBLs co-expressing Akt significantly inhibited
tumor growth comparing to PBLs expressing CAR only.
These data indicates that Akt transduction can increase
the activity of T cells in tumor environment and enhance
the anti-tumor efficacy of adoptively transferred tumor
specific T cells.
Discussion
In this study, we show that Akt activity of T cells is
down-regulated in tumor environment, and transducing
Akt increases the proliferation, cytokine production, and
anti-tumor effects of tumor specific T cells.
Akt phosphorylations in T cells incubated with tumor
culture supernatant or T cells isolated from TDLN were
inhibited (Fig. 1a and b), consistent with previous
findings that the activation status of Akt in T cells is a
primary determinant of T cell sensitivity to tumor im-
munosuppression [19]. It’s noticeable that OT-1 cells
transduced with myr-Akt didn’t shown further enhanced
effector functions than OT-1 cells transduced with
wtAkt, which was also demonstrated in PC3M tumor
Fig. 3 Adoptive transfer of OT-1 cells transduced with Akt can inhibit B16-OVA tumor growth and prolong mouse survival. OT-1 cells transduced
with control retroviruses or retroviruses encoding Akt or myr-Akt were intratumorally injected into B16-OVA tumor bearing mice at 2x106 cells/
mouse at 11 days after tumor challenge, and the mice without treatment were used as control. Tumor growth was monitored every other day,
and the death of mouse was defined when the tumor size reached 2 cm. a Line graph depicting the tumor volume of mice, statistical analysis
was performed using two-way ANOVA. b Kaplan-Meier survival analysis of transduced OT-1 treated or untreated mice. Comparison of survival
curves was made by Log-rank test
(See figure on previous page.)
Fig. 2 OT-1 cells transduced with Akt or myr-Akt display increased IFN-γ production and proliferation in the presence of B16-OVA tumor cells. a
OT-1 cells transduced with control retroviruses or retroviruses encoding Akt or myr-Akt were incubated with or without B16-OVA tumor cells at
an E:T ratio of 2:1, 24 h later, the cells were stained with anti-CD8 and anti-IFN-γ antibodies, and analyzed by flow cytometry. The analysis was
carried out with gated CD8+ population. b OT-1 cells transduced with control retroviruses or retroviruses encoding Akt or myr-Akt were labeled
with CFSE, and co-cultured with or without B16-OVA tumor cells at an E:T ratio of 2:1, 3 days later, the cells were stained with anti-CD8 antibody,
and analyzed by flow cytometry. The analysis was carried out with CD8+ population
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model. It could be partly explained by the similar phos-
phorylation levels of Akt observed for T cells transduced
with wtAkt and myr-Akt (Fig. 4c), also the increased
apoptosis observed for PBLs transduced with myr-Akt
cultured alone or in the presence of tumor cells (Fig. 5b).
The increased apoptosis observed for PBLs transduced
with myr-Akt is inconsistent with previous report that T
cells expressing constitutively active Akt up-regulated
anti-apoptotic molecules and displayed decreased apop-
tosis [20]. This difference could be caused by the differ-
ent experimental system used in their study, in which
the apoptosis was evaluated at 4 weeks after retrovirus
transduction, whereas our study characterized T cells at
5 days after transduction.
The increased apoptosis observed for myr-Akt trans-
duced T cells is contradictory to the well known pro-
Fig. 4 Engineer human peripheral blood lymphocytes (PBLs) to target prostate cancer cells. a Immunosuppressive phenotypes of human prostate
cancer cell line PC3M were examined by staining with HLA-DR, CD80, B7-H1, TGF-β, and IL-10. b Different constructs used to transduce PBLs, VH,
anti-human EpCAM immunoglobulin heavy chain variable region; VL, anti-human EpCAM immunoglobulin light chain variable region; CD28, part
of the extracellular domain and the entire transmembrane and intracellular domains of CD28; CD3ζ, the cytoplasmic domain of CD3ζ; IRES,
internal ribosome entry sequence. c Human PBLs were transduced with retroviruses encoding EpCAM specific CAR, CAR-Akt, or CAR-myr-Akt, at
5 days after transduction, the mRNA levels of transduced CAR were determined by RT-PCR and real-time PCR, and the protein levels of Akt,
phosphorylated Akt were determined by western blot
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Fig. 5 Over-expressing Akt increases the activity of CAR expressing PBLs in the presence of PC3M. PBLs transduced with CAR, CAR-Akt, or
CAR-myr-Akt were co-cultured with or without PC3M at an E:T ratio of 2:1, 3 days later, cell proliferation was examined by CFSE assay (a),
and cell apoptosis was determined by Annexin V/PI staining (b), the analysis was performed with gated CD8+ population
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survival role of Akt, however, it was reported that Akt
regulates Fas-mediated cell death through transcriptional
activation of Fas receptor [21]. In addition, it has also
been shown that Akt-dependent GSK inhibition regu-
lates activation induced cell death (AICD) of T cells [22].
It’s possible that over-expressing constitutively active
Akt increased AICD of T cells, thus dampened the
therapeutic efficacy of tumor specific T cells. The fact
that tumor specific T cells transduced with wtAkt dis-
played better effector functions than T cells transduced
with myr-Akt actually makes this strategy more conveni-
ent for clinical translation. Although it has been re-
ported that T cells expressing constitutively active Akt
still require antigen stimulation to grow [11], transdu-
cing constitutively active Akt raises safety concerns for
the application of this strategy. Our data supports over-
expressing wtAkt to enhance the therapeutic effects of
adoptively transferred tumor specific T cells, which
serves as a foundation for broader clinical translation.
OT-1 cells transduced with Akt produced IFN-γ and
increased the percentage of proliferative cells on expos-
ure to B16-OVA, indicating the specific activation of T
cells by tumor. In contrast, PBLs expressing CAR-Akt
co-cultured with PC3M displayed decreased prolifera-
tion and increased apoptosis comparing to cultured
alone, suggesting that PC3M model is more immuno-
suppressive, and up-regulating Akt is not sufficient to
enable T cells to completely resist the suppression. Des-
pite this, PBLs expressing CAR-Akt increased anti-
tumor effects both in vitro and in vivo, comparing to
PBLs expressing CAR only. It’s worth to mention that
the EpCAM specific CAR we used consists of both
CD28 and CD3ζ signaling domains, thus the increased
cytotoxicity displayed by PBLs co-expressing Akt is
probably due to resistance to inhibitory signaling con-
ferred by Akt activation.
The recent report by Crompton et al. found that inhib-
ition of Akt enabled TIL a memory T cell signature with
enhanced anti-tumor effect [23]. TILs isolated for adop-
tive transfer normally undergo extensive expansion
process in vitro, and display a terminally-differentiated
phenotype with short telomere and diminished anti-
tumor activity. In their study, Akt inhibitor was added
only in the expansion process, and they found that TILs
expanded with Akt inhibition persisted longer and
exerted better anti-tumor effects. Comparing to their
study, we used OT-1 T cells or PBLs stimulated and ex-
panded in vitro, which displayed a CD62L+ phenotype
after the short expansion process (Additional file 2:
Figure S2). Akt is necessary to induce and sustain ef-
fector functions of T cell [18, 24], comparing to their
study trying to enhance the persistence of T cells by in-
hibition of Akt, we tried to enhance the effector func-
tions of T cells by over-expressing Akt, these two studies
take different angles to manipulate T cells to enhance
the anti-tumor efficacy, and are not contradictory to
each other, and it’s worth further study to determine
which means is superior to the other. In addition, in their
work, tumor bearing mice were pretreated with total body
irradiation, adjuvant vaccine, and IL-2 in conjunction with
cell therapy, these preparations could ameliorate tumor
immunosuppression and enhance the anti-tumor effects
of cell therapy, however, severe adverse effects have been
reported. In contrast, we used adoptive cell therapy alone
to treat tumor, and over-expressing Akt could enable T
cells to resist tumor immunosuppression, which is the
major advantage of our strategy.
Conclusions
In summary, our data demonstrates that over-expressing
Akt in tumor specific T cells could improve the prolifer-
ation, cytokine production, and cytotoxicity of T cells in
Fig. 6 Over-expressing Akt enhances the anti-tumor efficacy of PBLs in vitro and in vivo. a PBLs transduced with CAR, CAR-Akt, or CAR-myr-Akt
were incubated with PC3M-luc at an E:T ratio of 2:1, 24 h later, cell viability was determined by luminescence imaging, and the luminescence
intensity was normalized to that of PC3M-luc cells without treatment. Statistical analysis was performed using student’s t-test. b NOD/SCID mice
were subcutaneously injected with PC3M tumor cells at 6 × 106 cells/mouse, at 21 days after tumor challenge, PBLs transduced with CAR,
CAR-Akt, or CAR-myr-Akt were intratumorally injected into mice at 3 × 106 cells/mouse, and the mice without treatment were used as control.
Tumor volume was measured every few days, and statistical analysis was performed using two-way ANOVA
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the presence of tumor. Comparing to strategies designed
to counteract various immunosuppressive mechanisms
employed by tumor, transducing Akt in T cells provides
a new approach for tumor immunotherapy, and has im-
portant implications for improving the therapeutic ef-
fects of adoptive T cell transfer.
Additional files
Additional file 1: Figure S1. Transduction efficiency of EpCAM CAR.
PBLs were transduced with CAR, CAR-Akt, or CAR-myr-Akt, 4 days later,
CAR expression was detected by biotinylated Protein L and PE conjugated
streptavidin. A) FACS histogram B) Quantification of transduction efficiency
of PBLs from 3 healthy donors. The untransduced PBLs were used as the
negative control. (JPEG 82 kb)
Additional file 2: Figure S2. CD62L expression on transduced PBLs.
PBLs were transduced with CAR, CAR-Akt, or CAR-myr-Akt, 4 days later,
the cells were stained with CD4, CD8, and CD62L. A) FACS histogram B)
Quantification of CD62L expression on CD4+ or CD8+ cells from 3 healthy
donors. (JPEG 790 kb)
Additional file 3: Figure S3. Quantification of cell proliferation and
apoptosis of transduced PBLs. PBLs transduced with CAR, CAR-Akt, or
CAR-myr-Akt were co-cultured with or without PC3M at an E:T ratio of
2:1, 3 days later, cell proliferation and apoptosis were determined. A)
Percent of CFSE+ cells in CD8+ population B) Percent of Annexin V+ cells
in CD8+ population. Experiments were repeated for 3 times, and statistical
analysis was performed using student’s t-test. (JPEG 99 kb)
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